Mylan to Buy Merck KGaA’s Generics Unit for $6.7 Billion

Mylan Laboratories (Canonsburg, PA) says it has agreed to buy Merck KGaA’s generic pharmaceuticals business for €4.9 billion ($6.7 billion) in cash. The sale price is in line with market expectations (CW, May 9, p. 6). Merck KGaA’s generics unit generated sales in 2006 of €1.8 billion, placing it fourth in the market behind Barr Pharmaceuticals (Woodcliff Lake, NJ), Novartis, and Teva Pharmaceutical Industries (Petach Tikva, Israel). Mylan and the Merck KGaA business will have a combined annual Ebitda of about $1 billion and sales of about...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers